Antibe Therapeutics (ATE) EPS Estimated At $-0.01; Cogentix Medical (CGNT) Had 3 Bulls

November 15, 2017 - By Michael Collier

Among 3 analysts covering Cogentix Medical (NASDAQ:CGNT), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cogentix Medical had 7 analyst reports since November 5, 2015 according to SRatingsIntel. The stock of Cogentix Medical Inc (NASDAQ:CGNT) has “Buy” rating given on Friday, October 6 by JMP Securities. Roth Capital upgraded Cogentix Medical Inc (NASDAQ:CGNT) on Thursday, November 5 to “Buy” rating. Roth Capital maintained the shares of CGNT in report on Wednesday, November 8 with “Buy” rating. Roth Capital maintained the shares of CGNT in report on Tuesday, July 18 with “Buy” rating. The rating was upgraded by TH Capital to “Buy” on Thursday, November 5. The rating was downgraded by Roth Capital on Friday, May 6 to “Neutral”. The rating was maintained by Roth Capital with “Buy” on Wednesday, August 2. See Cogentix Medical Inc (NASDAQ:CGNT) latest ratings:

08/11/2017 Broker: Roth Capital Old Rating: Buy New Rating: Buy New Target: $4 Maintain
06/10/2017 Broker: JMP Securities Rating: Buy New Target: $5.0 Initiate
02/08/2017 Broker: Roth Capital Rating: Buy New Target: $3.0000 Maintain
18/07/2017 Broker: Roth Capital Rating: Buy New Target: $2.3000 Maintain

Analysts expect Antibe Therapeutics Inc (CVE:ATE) to report $-0.01 EPS on December, 5.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.01 EPS. After having $-0.02 EPS previously, Antibe Therapeutics Inc’s analysts see -50.00% EPS growth. The stock increased 5.56% or $0.005 on November 14, reaching $0.095. About 499,000 shares traded or 97.41% up from the average. Antibe Therapeutics Inc (CVE:ATE) has 0.00% since November 15, 2016 and is . It has underperformed by 16.70% the S&P500.

Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The company has market cap of $15.48 million. The Firm is focused on pain, inflammation and regenerative medicine. It currently has negative earnings. The Company’s divisions include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places.

The stock increased 1.89% or $0.05 on November 14, reaching $2.7. About shares traded. Cogentix Medical Inc (NASDAQ:CGNT) has risen 83.33% since November 15, 2016 and is uptrending. It has outperformed by 66.63% the S&P500.

Cogentix Medical, Inc. is a global medical device company. The company has market cap of $164.47 million. The Firm designs, develops, makes and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. It currently has negative earnings. The Firm also offers the Urgent PC Neuromodulation System , a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office treatment of overactive bladder (OAB).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com